NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

abeta, those percentages are estimates for the treatment arm (232 patients). So if a patient with GBM receives the current standard of care plus DCVax, that would be their chances of living that long. It would be a huge advancement from the current standard of care, and may provide some hope for Glioblastoma patients. I think Northwest Bio is attempting to identify who is likely to benefit from this treatment, and will also combine DCVax with other immunotherapies, which should improve those percentages in the future. (and potentially eliminate toxic chemotherapy)

As longfellow said, the current alive number is a bit irrelevant to this percentage since this trial has been going on for 13 years and some of those early patients whose lives may have been extended by 3, 4, 5 or more years, could have passed by now.